Novel two-chain structure utilizing KIRS2/DAP12 domain improves the safety and efficacy of CAR-T cells in adults with r/r B-ALL
Open Access
- 28 August 2021
- journal article
- research article
- Published by Elsevier in Molecular Therapy-Oncolytics
- Vol. 23, 96-106
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
- Natural Science Foundation of Guangxi Province
- Natural Science Foundation of Jiangsu Province
This publication has 31 references indexed in Scilit:
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaNew England Journal of Medicine, 2017
- Mitochondrial Priming by CD28Cell, 2017
- The Principles of Engineering Immune Cells to Treat CancerCell, 2017
- Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T CellsCancer Cell, 2015
- The pharmacology of second-generation chimeric antigen receptorsNature Reviews Drug Discovery, 2015
- Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric ImmunoreceptorsCancer Immunology Research, 2015
- 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptorsNature Medicine, 2015
- Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolutionNature Reviews Immunology, 2013
- CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patientsJournal of Clinical Investigation, 2011
- DAP10‐ and DAP12‐associated receptors in innate immunityImmunological Reviews, 2008